Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

ZW25 > Overview of Zanidatamab > Flashcards

Overview of Zanidatamab Flashcards

1
Q

Therapeutic antibodies can be made in the lab T/F?

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

During an immune response antibodies bind to specific portions of their target molecules called____________

A

Epitopes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The scFv of Zanidatamab binds to

A

ECD 4 of HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ECD4 is known as ____________

A

Juxtamembrane extracellular receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Fab of Zanidatamab binds to

A

ECD 2 of HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ECD2 is known as_______________

A

The dimerization domain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Hercetin binds to ______

A

ECD 4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Perjeta binds to ______

A

ECD 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Zanidatamab causes __________ of HER 2 molecules

A

Crosslinking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Crosslinking leads to

A

HER2 : Clustering, Internalization, Downregulation, Inhibition and Triggering

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Immune mediated responses include:

A

ADCC, ADCP and CDC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Phase 1 study implemented a ______ trial design

A

Basket

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Part 1 was designed to identify

A

Maximum tolerated dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cohort 5 of Part included

A

22 patients with HER2 + BTC
13 GBC, 4 eCCA, 5 iCCA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Part 2 was to characterize

A

Safety, tolerability and preliminary anti tumor activity of zanidatamab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Part 2 was to evaluate _____

A

Zanidatamab with chemotherapy in patients with HER2 expressing breast and GEA

15
Q

What was the primary endpoint of Part 2 Cohort 5 study?

A

Safety

16
Q

Key secondary endpoints were?

A

ORR, DCR, PFS

17
Q

The median age was ________

A

62.5 years

18
Q

_____ patients _____% with BTC had a partial response

A

8, 38%

19
Q

ORR in Part 2 was ______

A

38%

20
Q

Median DCR in Part 2 was ____

A

62%

21
Q

mPFS in part 2 was______

A

3.5 months

22
Q

Most common AE’s in Phase 1 were____

A

Diarrhea, Infusion reaction, fatigue and rash

ZW25 (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions